Pharmacogenetics: Implications for therapy in rheumatic diseases

Lesley Davila, Prabha Ranganathan

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

DMARDs not only improve the joint pain and swelling associated with rheumatoid arthritis (RA), but also slow down the joint damage associated with the disease. The efficacy of biologic therapies, introduced in the past decade for the treatment of RA, has been unequivocally established. Similarly, in addition to traditional drugs such as hydroxychloroquine, new biologic agents such as rituximab have been introduced for systemic lupus erythematosus in recent years. However, considerable variability occurs in the responses of patients to these therapies. Pharmacogenetics, the study of variations in genes encoding drug transporters, drug-metabolizing enzymes and drug targets, and their translation to differential responses to drugs, is a rapidly progressing field in rheumatology. Pharmacogenetic applications, particularly to the old vanguard DMARD, methotrexate, and the newer, more expensive biologic agents, might make personalized therapy in rheumatic diseases possible. The pharmacogenetics of commonly used DMARDs and of biologic therapies are described in this Review.

Original languageEnglish (US)
Pages (from-to)537-550
Number of pages14
JournalNature Reviews Rheumatology
Volume7
Issue number9
DOIs
StatePublished - Sep 2011

Fingerprint

Pharmacogenetics
Rheumatic Diseases
Antirheumatic Agents
Biological Therapy
Pharmaceutical Preparations
Biological Factors
Rheumatoid Arthritis
Hydroxychloroquine
Therapeutics
Arthralgia
Rheumatology
Methotrexate
Systemic Lupus Erythematosus
Joints
Enzymes
Genes

ASJC Scopus subject areas

  • Rheumatology

Cite this

Pharmacogenetics : Implications for therapy in rheumatic diseases. / Davila, Lesley; Ranganathan, Prabha.

In: Nature Reviews Rheumatology, Vol. 7, No. 9, 09.2011, p. 537-550.

Research output: Contribution to journalArticle

@article{e0a39a95e03d44118283c11b9182d633,
title = "Pharmacogenetics: Implications for therapy in rheumatic diseases",
abstract = "DMARDs not only improve the joint pain and swelling associated with rheumatoid arthritis (RA), but also slow down the joint damage associated with the disease. The efficacy of biologic therapies, introduced in the past decade for the treatment of RA, has been unequivocally established. Similarly, in addition to traditional drugs such as hydroxychloroquine, new biologic agents such as rituximab have been introduced for systemic lupus erythematosus in recent years. However, considerable variability occurs in the responses of patients to these therapies. Pharmacogenetics, the study of variations in genes encoding drug transporters, drug-metabolizing enzymes and drug targets, and their translation to differential responses to drugs, is a rapidly progressing field in rheumatology. Pharmacogenetic applications, particularly to the old vanguard DMARD, methotrexate, and the newer, more expensive biologic agents, might make personalized therapy in rheumatic diseases possible. The pharmacogenetics of commonly used DMARDs and of biologic therapies are described in this Review.",
author = "Lesley Davila and Prabha Ranganathan",
year = "2011",
month = "9",
doi = "10.1038/nrrheum.2011.117",
language = "English (US)",
volume = "7",
pages = "537--550",
journal = "Nature Reviews Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "9",

}

TY - JOUR

T1 - Pharmacogenetics

T2 - Implications for therapy in rheumatic diseases

AU - Davila, Lesley

AU - Ranganathan, Prabha

PY - 2011/9

Y1 - 2011/9

N2 - DMARDs not only improve the joint pain and swelling associated with rheumatoid arthritis (RA), but also slow down the joint damage associated with the disease. The efficacy of biologic therapies, introduced in the past decade for the treatment of RA, has been unequivocally established. Similarly, in addition to traditional drugs such as hydroxychloroquine, new biologic agents such as rituximab have been introduced for systemic lupus erythematosus in recent years. However, considerable variability occurs in the responses of patients to these therapies. Pharmacogenetics, the study of variations in genes encoding drug transporters, drug-metabolizing enzymes and drug targets, and their translation to differential responses to drugs, is a rapidly progressing field in rheumatology. Pharmacogenetic applications, particularly to the old vanguard DMARD, methotrexate, and the newer, more expensive biologic agents, might make personalized therapy in rheumatic diseases possible. The pharmacogenetics of commonly used DMARDs and of biologic therapies are described in this Review.

AB - DMARDs not only improve the joint pain and swelling associated with rheumatoid arthritis (RA), but also slow down the joint damage associated with the disease. The efficacy of biologic therapies, introduced in the past decade for the treatment of RA, has been unequivocally established. Similarly, in addition to traditional drugs such as hydroxychloroquine, new biologic agents such as rituximab have been introduced for systemic lupus erythematosus in recent years. However, considerable variability occurs in the responses of patients to these therapies. Pharmacogenetics, the study of variations in genes encoding drug transporters, drug-metabolizing enzymes and drug targets, and their translation to differential responses to drugs, is a rapidly progressing field in rheumatology. Pharmacogenetic applications, particularly to the old vanguard DMARD, methotrexate, and the newer, more expensive biologic agents, might make personalized therapy in rheumatic diseases possible. The pharmacogenetics of commonly used DMARDs and of biologic therapies are described in this Review.

UR - http://www.scopus.com/inward/record.url?scp=80052393117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80052393117&partnerID=8YFLogxK

U2 - 10.1038/nrrheum.2011.117

DO - 10.1038/nrrheum.2011.117

M3 - Article

C2 - 21826093

AN - SCOPUS:80052393117

VL - 7

SP - 537

EP - 550

JO - Nature Reviews Rheumatology

JF - Nature Reviews Rheumatology

SN - 1759-4790

IS - 9

ER -